Glenmark Pharma receives ANDA approval for Adapalene and Benzoyl Peroxide gel.

According to IQVIATM sales data for the 12 month period ending September 2019, the Epiduo® Gel,  0.1%|2.5% market2 achieved annual sales of approximately $33.7 million*.          Glenmark’s current portfolio consists of  163 products authorized for distribution in the  U.S. marketplace and 45 ANDA’s pending approval with the  U.S.  FDA.  In addition to these internal filings, Glenmark continues to  identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.